278 related articles for article (PubMed ID: 17482818)
21. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
[TBL] [Abstract][Full Text] [Related]
22. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
[TBL] [Abstract][Full Text] [Related]
24. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
Andrews DM; Carey SJ; Chaignot H; Coomber BA; Gray NM; Hind SL; Jones PS; Mills G; Robinson JE; Slater MJ
Org Lett; 2002 Dec; 4(25):4475-8. PubMed ID: 12465916
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
26. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
Chen KX; Nair L; Vibulbhan B; Yang W; Arasappan A; Bogen SL; Venkatraman S; Bennett F; Pan W; Blackman ML; Padilla AI; Prongay A; Cheng KC; Tong X; Shih NY; Njoroge FG
J Med Chem; 2009 Mar; 52(5):1370-9. PubMed ID: 19196021
[TBL] [Abstract][Full Text] [Related]
27. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
Bilodeau F; Bailey MD; Bhardwaj PK; Bordeleau J; Forgione P; Garneau M; Ghiro E; Gorys V; Halmos T; Jolicoeur ES; Leblanc M; Lemke CT; Naud J; O'Meara J; White PW; Llinàs-Brunet M
Bioorg Med Chem Lett; 2013 Jul; 23(14):4267-71. PubMed ID: 23735741
[TBL] [Abstract][Full Text] [Related]
29. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
30. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
[TBL] [Abstract][Full Text] [Related]
31. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
[TBL] [Abstract][Full Text] [Related]
32. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
33. Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
Andrews DM; Barnes MC; Dowle MD; Hind SL; Johnson MR; Jones PS; Mills G; Patikis A; Pateman TJ; Redfern TJ; Robinson JE; Slater MJ; Trivedi N
Org Lett; 2003 Nov; 5(24):4631-4. PubMed ID: 14627401
[TBL] [Abstract][Full Text] [Related]
34. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
[No Abstract] [Full Text] [Related]
35. Inhibitors of the hepatitis C virus NS3 protease with basic amine functionality at the P3-amino acid N-terminus: discovery and optimization of a new series of P2-P4 macrocycles.
Harper S; Ferrara M; Crescenzi B; Pompei M; Palumbi MC; DiMuzio JM; Donghi M; Fiore F; Koch U; Liverton NJ; Pesci S; Petrocchi A; Rowley M; Summa V; Gardelli C
J Med Chem; 2009 Aug; 52(15):4820-37. PubMed ID: 19624135
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
Li X; Liu Y; Zhang YK; Plattner JJ; Baker SJ; Bu W; Liu L; Zhou Y; Ding CZ; Zhang S; Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A
Bioorg Med Chem Lett; 2012 Dec; 22(24):7351-6. PubMed ID: 23142614
[TBL] [Abstract][Full Text] [Related]
37. Macrocyclic inhibitors of HCV NS3 protease.
Venkatraman S; Njoroge FG
Expert Opin Ther Pat; 2009 Sep; 19(9):1277-303. PubMed ID: 19563268
[TBL] [Abstract][Full Text] [Related]
38. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
39. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
40. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
Bachmetov L; Gal-Tanamy M; Shapira A; Vorobeychik M; Giterman-Galam T; Sathiyamoorthy P; Golan-Goldhirsh A; Benhar I; Tur-Kaspa R; Zemel R
J Viral Hepat; 2012 Feb; 19(2):e81-8. PubMed ID: 22239530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
